Animal Models of Idiosyncratic Drug Reactions

Advances in Pharmacology

Volumn 63, Issue , 2012, Pages 81-135

  Ng, Winnie ^a   Lobach, Alexandra R M ^a   Zhu, Xu ^a   Chen, Xin ^a   Liu, Feng ^a   Metushi, Imir G ^b   Sharma, Amy ^a   Li, Jinze ^a,c   Cai, Ping ^a   Ip, Julia ^a   Novalen, Maria ^a   Popovic, Marija ^a,d   Zhang, Xiaochu ^a   Tanino, Tadatoshi ^a,e   Nakagawa, Tetsuya ^a,f   Li, Yan ^g   Uetrecht, Jack ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BRISTOL MYERS SQUIBB   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e KINKI UNIVERSITY   (Japan)

^f DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^g Drug Development Therapure Biopharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHYDRAZIDE; ALANINE AMINOTRANSFERASE; AMINOGLUTETHIMIDE; AMINOPHENAZONE; AMODIAQUINE; CLOZAPINE; CYTOKINE; DNA; DRUG METABOLITE; FELBAMATE; HALOTHANE; HYDRALAZINE; HYDRAZINE; INTERLEUKIN 17; ISONIAZID; MAJOR HISTOCOMPATIBILITY ANTIGEN; MANGANESE SUPEROXIDE DISMUTASE; MERCURY; MONOCARBAMATE FELBAMATE; NEVIRAPINE; PARACETAMOL; PENICILLAMINE; PROCAINAMIDE; PROPYLTHIOURACIL; RANITIDINE; SULFONAMIDE; T LYMPHOCYTE RECEPTOR; TRIFLUOROACETYL CHLORIDE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; ASCORBIC ACID DEFICIENCY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD DYSCRASIA; DNA METHYLATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTHYROIDISM; IDIOSYNCRATIC DRUG REACTION; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; KIDNEY INJURY; LIVER INJURY; LIVER TOXICITY; LUPUS LIKE SYNDROME; MACROPHAGE; MALARIA; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RASH; RHEUMATOID ARTHRITIS; RISK FACTOR; SELENIUM DEFICIENCY; STEVENS JOHNSON SYNDROME; TH17 CELL; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE;

EID: 84863749250     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-398339-8.00003-3     Document Type: Chapter

References (199)

1. Adams D.H., Ju C., Ramaiah S.K., Uetrecht J., Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicological Sciences 2010, 115:307-321.
2. Ali H., Khalaf L., Nicholls P.J., Poole A. Comparison of in vitro and in vivo haemotoxic effects of aminoglutethimide and glutethimide. Toxicology In Vitro 1990, 4:381-383.
3. Aloush V., Litinsky I., Caspi D., Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Seminars in Arthritis and Rheumatism 2006, 36:4-9.
4. Antunes A.M., Duarte M.P., Santos P.P., da Costa G.G., Heinze T.M., Beland F.A., et al. Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine. Chemical Research in Toxicology 2008, 21:1443-1456.
5. Antunes A.M., Godinho A.L., Martins I.L., Justino G.C., Beland F.A., Marques M.M. Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine-a possible factor in nevirapine toxicity. Chemical Research in Toxicology 2010, 23:888-899.
6. Antunes A.M., Godinho A.L., Martins I.L., Oliveira M.C., Gomes R.A., Coelho A.V., et al. Protein adducts as prospective biomarkers of nevirapine toxicity. Chemical Research in Toxicology 2010, 23:1714-1725.
7. Aten J., Bosman C.B., Rozing J., Stijnen T., Hoedemaeker P.J., Weening J.J. Mercuric chloride-induced autoimmunity in the brown Norway rat. Cellular kinetics and major histocompatibility complex antigen expression. American Journal of Pathology 1988, 133:127-138.
8. Aucoin D.P., Peterson M.E., Hurvitz A.I., Drayer D.E., Lahita R.G., Quimby F.W., et al. Propylthiouracil-induced immune-mediated disease in the cat. Journal of Pharmacology and Experimental Therapeutics 1985, 234:13-18.
9. Aucoin D.P., Rubin R.L., Peterson M.E., Reidenberg M.M., Drayer D.E., Hurvitz A.I., et al. Dose dependent induction of anti-native DNA antibodies in cats by propylthiouracil. Arthritis & Rheumatism 1988, 31:688-692.
10. Bagenstose L.M., Salgame P., Monestier M. Cytokine regulation of a rodent model of mercuric chloride-induced autoimmunity. Environmental Health Perspectives 1999, 107(Suppl. 5):807-810.
11. Bersoff-Matcha S.J., Miller W.C., Aberg J.A., van Der Horst C., Hamrick H.J., Powderly W.G., et al. Sex differences in nevirapine rash. Clinical Infectious Diseases 2001, 32:124-129.
12. Boelsterli U.A., Hsiao C.J.J. The heterozygous Sod2+/- mouse: modeling the mitochondrial role in drug toxicity. Drug Discovery Today 2008, 13:982-988.
13. Bourdi M., Amouzadeh H.R., Rushmore T.H., Martin J.L., Pohl L.R. Halothane-induced liver injury in outbred guinea pigs: role of trifluoroacetylated protein adducts in animal susceptibility. Chemical Research in Toxicology 2001, 14:362-370.
14. Bourdi M., Masubuchi Y., Reilly T.P., Amouzadeh H.R., Martin J.L., George J.W., et al. Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 2002, 35:289-298.
15. Cai P., Nakagawa T., Uetrecht J. Development of an animal model of amodiaquine-induced liver injury. The Toxicologist 2011, 120:90.
16. Cai P., Uetrecht J. Amodiaquine-induced liver toxicity in the rat. The Toxicologist 2009, 108:238.
17. Chen J., Mannargudi B.M., Xu L., Uetrecht J. Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chemical Research in Toxicology 2008, 21:1862-1870.
18. Chen M., Gandolfi J. Characterization of the humoral immune response and hepatotoxicity after multiple halothane exposures in guinea pigs. Drug Metabolism Reviews 1997, 29:103-122.
19. Chen X., Tharmanathan T., Mannargudi B., Gou H., Uetrecht J.P. A study of the specificity of lymphocytes in nevirapine-induced skin rash. Journal of Pharmacology and Experimental Therapeutics 2009, 331:836-841.
20. Chen Y., Sun R. Toll-like receptors in acute liver injury and regeneration. International Immunopharmacology 2011, 10.1016/j.intimp.2011.1004.1023.
21. Cheng L., You Q., Yin H., Holt M.P., Ju C. Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochemical Pharmacology 2010, 80:255-261.
22. Christie G., Breckenridge A.M., Park B.K. Drug-protein conjugates-XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochemical Pharmacology 1989, 38:1451-1458.
23. Chu K.M., Boulle A.M., Ford N., Goemaere E., Asselman V., Van Cutsem G. Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. PLoS One 2010, 5:e9183.
24. Clarke J.B., Maggs J.L., Kitteringham N.R., Park B.K. Immunogenicity of amodiaquine in the rat. International Archives of Allergy & Applied Immunology 1990, 91:335-342.
25. Clarke J.B., Neftel K., Kitteringham N.R., Park B.K. Detection of antidrug IgG antibodies in patients with adverse drug reactions to amodiaquine. International Archives of Allergy & Applied Immunology 1991, 95:369-375.
26. Clay K.D., Hanson J.S., Pope S.D., Rissmiller R.W., Purdum P.P., Banks P.M. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Annals of Internal Medicine 2006, 144:415-420.
27. Cocconi G. First generation aromatase inhibitors-aminoglutethimide and testololactone. Breast Cancer Research and Treatment 1994, 30:57-80.
28. Coleman M.D., Khalaf L.F., Nicholls P.J. Aminoglutethimide-induced leucopenia in a mouse model: effects of metabolic and structural determinates. Environmental Toxicology and Pharmacology 2003, 15:27-32.
29. Connolly M.K., Ayo D., Malhotra A., Hackman M., Bedrosian A.S., Ibrahim J., et al. Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. Hepatology 2011, 10.1002/hep.24429.
30. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autroreactivity. Journal of Immunology 1988, 140:2197-2200.
31. Cribb A.E., Lee B.L., Trepanier L.A., Spielberg S.P. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug Reactions and Toxicological Reviews 1996, 15:9-50.
32. Dahlin D.C., Miwa G.T., Lu A.Y., Nelson S.D. N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. The Proceedings of the National Academy of Sciences USA 1984, 81:1327-1331.
33. Degoul F., Sutton A., Mansouri A., Cepanec C., Degott C., Fromenty B., et al. Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. Gastroenterology 2001, 120:1468-1474.
34. Deng C., Lu Q., Zhang Z., Rao T., Attwood J., Yung R., et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis & Rheumatism 2003, 48:746-756.
35. Deng X., Luyendyk J.P., Ganey P.E., Roth R.A. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacological Reviews 2009, 61:262-282.
36. Deng X., Stachlewitz R.F., Liguori M.J., Blomme E.A.G., Waring J.F., Luyendyk J.P., et al. Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. Journal of Pharmacology and Experimental Therapeutics 2006, 319:1191-1199.
37. Diao H., Kon S., Iwabuchi K., Kimura C., Morimoto J., Ito D., et al. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004, 21:539-550.
38. Dieckhaus C.M., Miller T.A., Sofia R.D., Macdonald T.L. A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metabolism and Disposition 2000, 28:814-822.
39. Dieckhaus C.M., Roller S.G., Santos W.L., Sofia R.D., Macdonald T.L. Role of gluathione-S-transferases A1-1, M1-1, P1-1 in the detoxificaiton of 2-phenylpropenal, a reactive felbamate metabolite. Chemical Research in Toxicology 2001, 2001:511-516.
40. Dieterich D.T., Robinson P.A., Love J., Stern J.O. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clinical Infectious Diseases 2004, 38(Suppl. 2):80-89.
41. Donker A.J., Venuto R.C., Vladutiu A.O., Brentjens J.R., Andres G.A. Effects of prolonged administration of d-penicillamine or captopril in various strains of rats. Brown Norway rats treated with d-penicillamine develop autoantibodies, circulating immune complexes, and disseminated intravascular coagulation. Clinical Immunology and Immunopathology 1984, 30:142-155.
42. Egger H., Bartlett F., Itterly W., Rodebaugh R., Shimanskas C. Metabolism of aminoglutethimide in the rat. Drug Metabolism and Disposition 1982, 10:405-412.
43. Eghtesadi-Araghi P. Halothane hepatitis in Iran: a review of 59 cases. World Journal of Gastroenterology 2008, 14:5322.
44. Elsheikh A., Lavergne S.N., Castrejon J.L., Farrell J., Wang H., Sathish J., et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. Journal of Immunology 2010, 185:6448-6460.
45. Fan H., Cook J.A. Molecular mechanisms of endotoxin tolerance. Journal of Endotoxin Research 2004, 10:71-84.
46. Ferguson N.M., Novak A.F. Attempts at induced agranulocytosis in rats using dipyrone. The Journal of Pharmaceutical Sciences 1966, 55:1306-1308.
47. Fibbe W.E., Claas F.H.J., Van der Star-Dijlstra W., Schaafsma M.R., Meyboom R.H.B., Falkenburg J.H.F. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. British Journal of Haematology 1986, 64:363-373.
48. Fishel B., Tishler M., Caspi D., Yaron M. Fatal aplastic anaemia and liver toxicity caused by d-penicillamine treatment of rheumatoid arthritis. Annals of Rheumatic Diseases 1989, 48:609-610.
49. Fournie G.J., Saoudi A., Druet P., Pelletier L. Th2-type immunopathological manifestations induced by mercury chloride or gold salts in the rat: signal transduction pathways, cellular mechanisms and genetic control. Autoimmunity Reviews 2002, 1:205-212.
50. Fujimoto K., Kumagai K., Ito K., Arakawa S., Ando Y., Oda S.I, et al. Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicologic Pathology 2009, 37:193-200.
51. Furst S.M., Luedke D., Gaw H.H., Reich R., Gandolfi A.J. Demonstration of a cellular immune response in halothane-exposed guinea pigs. Toxicology and Applied Pharmacology 1997, 143:245-255.
52. Gardner I., Leeder J.S., Chin T., Zahid N., Uetrecht J.P. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Molecular Pharmacology 1998, 53:999-1008.
53. Gatanaga H., Yazaki H., Tanuma J., Honda M., Genka I., Teruya K., et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007, 21:264-265.
54. Gong Y., Klingenberg S.L., Gluud C. Systematic review and meta-analysis: d-Penicillamine vs. placebo/no intervention in patients with primary biliary cirrhosis-Cochrane Hepato-Biliary Group. Alimentary Pharmacology & Therapeutics 2006, 24:1535-1544.
55. Goss P.E., Jarman M., Griggs L.J. Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism. British Journal of Cancer 1985, 51:259-262.
56. Grant S.M., Langtry H.D., Brogden R.N. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989, 37:801-870.
57. Guest I., Sokoluk B., MacCrimmon J., Uetrecht J. Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 1998, 131:53-65.
58. Harris A.L., Hughes G., Barrett A.J., Abusrewil S., Dowsett M., Smith I.E. Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies. British Journal of Cancer 1986, 54:119-122.
59. Harrison A.C., Kitteringham N.R., Clarke J.B., Park B.K. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochemical Pharmacology 1992, 43:1421-1430.
60. Hastings K.L., Thomas C., Brown A.P., Gandolfi A.J. Trifluoroacetylation potentiates the humoral immune response to halothane in the guinea pig. Immunopharmacology and Immunotoxicology 1995, 17:201-213.
61. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. Journal of Autoimmunity 2009, 33:3-11.
62. Hoffman A.M., Butt E.M., Hickey N.G. Neutropenia following amidopyrine. JAMA 1934, 102:1213-1214.
63. Horn D.M., Neeb L.A., Colacino J.M., Richardson F.C. Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria. Antiviral Research 1997, 34:71-74.
64. Howard-Lock H.E., Lock C.J., Mewa A., Kean W.F. d-penicillamine: chemistry and clinical use in rheumatic disease. Seminars in Arthritis and Rheumatism 1986, 15:261-281.
65. Hughes S.W.M., Burley D.M. Aminoglutethimide: a 'side-effect' turned therapeutic advantage. Postgraduate Medical Journal 1970, 46:409-416.
66. Hultman P., Enestrom S. Dose-response studies in murine mercury-induced autoimmunity and immune-complex disease. Toxicology and Applied Pharmacology 1992, 113:199-208.
67. Hultman P., Hansson-Georgiadis H. Methyl mercury-induced autoimmunity in mice. Toxicology and Applied Pharmacology 1999, 154:203-211.
68. Husain Z., Pinto C., Sofia R.D., Yunis E.J. Felbamate-induced apoptosis of hematopoietic cells is mediated by redox-sensitive and redox-independent pathways. Epilepsy Research 2002, 48:57-69.
69. Iorio R., D'Ambrosi M., Marcellini M., Barbera C., Maggiore G., Zancan L., et al. Serum transaminases in children with Wilsons disease. Journal of Pediatric Gastroenterology and Nutrition 2004, 39:331-336.
70. Ip J., Uetrecht J. In vitro and animal models of drug-induced blood dyscrasias. Environmental Toxicology and Pharmacology 2006, 21:135-140.
71. Ip J., Uetrecht J.P. Testing the hypothesis that selenium deficiency is a risk factor for clozapine-induced agranulocytosis in rats. Chemical Research in Toxicology 2008, 21:874-878.
72. Ip J., Wilson J.X., Uetrecht J.P. Testing the hypothesis that vitamin C deficiency is a risk factor for clozapine-induced agranulocytosis using guinea pigs and ODS rats. Chemical Research in Toxicology 2008, 21:869-873.
73. Ip J.R.T. Investigation of The Mechanisms of Drug-induced Agranulocytosis 2009, University of Toronto, Toronto, ON, (Doctoral dissertation).
74. Iverson S., Kautiainen A., Ip J., Uetrecht J.P. Effect of clozapine on neutrophil kinetics in rabbits. Chemical Research in Toxicology 2010, 23:1184-1191.
75. Jaeschke H. Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?. Toxicological Sciences 2007, 97:1-3.
76. Jaeschke H., Williams C.D., Ramachandran A., Bajt M.L. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver International 2011, 10.1111/j.1478-3231.2011.02501.x.
77. Jollow D.J., Mitchell J.R., Potter W.Z., Davis D.C., Gillette J.R., Brodie B.B. Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. Journal of Pharmacology and Experimental Therapeutics 1973, 187:195-202.
78. Ju C., Reilly T.P., Bourdi M., Radonovich M.F., Brady J.N., George J.W., et al. Protective role of Kupffer cells in acetaminophen-induced hepatic injury in mice. Chemical Research in Toxicology 2002, 15:1504-1513.
79. Kashimshetty R., Desai V.G., Kale V.M., Lee T., Moland C.L., Branham W.S., et al. Underlying mitochondrial dysfunction triggers flutamide-induced oxidative liver injury in a mouse model of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 2009, 238:150-159.
80. Kass G.E. Mitochondrial involvement in drug-induced hepatic injury. Chemico-Biological Interactions 2006, 163:145-159.
81. Kaufman D.W., Kelly J.P., Anderson K.T., Harmon D.C., Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997, 38:1265-1269.
82. Keane N.M., Nolan D., Phillips E.J., Lucas A.D., Almeida C.A., Martin A.M., et al. Use of the ELISpot assay to detect abacavir- and nevirapine-induced IFN- responses in PBMC from HIV-infected patients with abacavir or nevirpine hypersensitivity reactions 2007, Paper presented at the the 4th International AIDS Society Meeting, Sydney, Australia.
83. Kharasch E.D. Adverse drug reactions with halogenated anesthetics. Clinical Pharmacology & Therapeutics 2008, 84:158-162.
84. Kobayashi E., Kobayashi M., Tsuneyama K., Fukami T., Nakajima M., Yokoi T. Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicological Sciences 2009, 111:302-310.
85. Kokoszka J.E., Coskun P., Espositio L.A., Wallace D.C. Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proceedings of the Academy of Natural Sciences 2001, 98:2278-2283.
86. Kretz-Rommel A., Duncan S.R., Rubin R.L. Autoimmunity caused by disruption of central T cell tolerance: a murine model of drug-induced lupus. Journal of Clinical Investigations 1997, 99:1888-1896.
87. Kumar A., Bhat A., Gupta D.K., Goel A., Malaviya A.N. d-Penicillamine-induced acute hypersensitivity pneumonitis and cholestatic hepatitis in a patient with rheumatoid arthritis. Clinical and Experimental Rheumatology 1985, 3:337-339.
88. Langier S., Sade K., Kivity S. Regulatory T cells: the suppressor arm of the immune system. Autoimmunity Reviews 2010, 10:112-115.
89. Lavergne S.N., Danhof R.S., Volkman E.M., Trepanier L.A. Association of drug-serum protein adducts and anti-drug antibodies in dogs with sulphonamide hypersensitivity: a naturally occurring model of idiosyncratic drug toxicity. Clinical & Experimental Allergy 2006, 36:907-915.
90. Lavergne S.N., Drescher N.J., Trepanier L.A. Anti-myeloperoxidase and anti-cathepsin G antibodies in sulphonamide hypersensitivity. Clinical & Experimental Allergy 2007, 38:199-207.
91. Lavergne S.N., Volkman E.M., Maki J.E., Yoder A.R., Trepanier L.A. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study. Toxicology 2005, 208:63-72.
92. Lebovitz R.M., Zhang H., Vogel H., Cartwright J., Dionne L., Lu N., et al. Neurodegeneration myocardial injury and perinatal death in mitochondrial superoxidase dismutase deficient mice. Proceedings of the Academy of Natural Sciences 1996, 93:9782-9787.
93. Lee Y.H., Chung M.C.M., Lin Q., Boelsterli U.A. Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2+/- mice: two-stage oxidative injury. Toxicology and Applied Pharmacology 2008, 231:43-51.
94. Leone A.M., Kao L.M., McMillian M.K., Nie A.Y., Parker J.B., Kelley M.F., et al. Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chemical Research in Toxicology 2007, 20:600-608.
95. Li J., Kourteva G., Hilton H., Cai P., Workman H., Haggerty H., et al. Changes in hepatic gene expression induced by amodiaquine in rats. The Toxicologist 2011, 120:323.
96. Li J., Mannargudi B., Uetrecht J.P. Covalent binding of penicillamine to macrophages: implications for penicillamine-induced autoimmunity. Chemical Research in Toxicology 2009, 22:1277-1284.
97. Li J., Uetrecht J. The danger hypothesis as applied to idiosyncratic drug reactions. Handbook of Experimental Pharmacology 2010, 196:493-509.
98. Li J., Uetrecht J.P. d-Penicillamine-induced autoimmunity: relationship to macrophage activation. Chemical Research in Toxicology 2009, 22:1526-1533.
99. Li J., Workman H., Cai P., Kourteva G., Hilton H., Haggerty H., et al. Immunological aspects of an animal model of amodiaquine-induced liver toxicity. The Toxicologist 2011, 120:323.
100. Liu F., Cai P., Li J., Uetrecht J. Study of liver lymphocytes in amodiaquine-induced hepatotoxicity in Brown Norway rats. The Toxicologist 2011, 120:93.
101. Liu Z.C., Uetrecht J.P. Clozapine is oxidized by activated human neutrophils to a reactive nitrinium ion that irreversibly binds to the cells. Journal of Pharmacology and Experimental Therapeutics 1995, 275:1476-1483.
102. Lohse A.W., Manns M., Dienes H.P., Meyer zum Buschenfelde K.H., Cohen I.R. Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology 1990, 11:24-30.
103. Luyendyk J.P., Maddox J.F., Cosma G.N., Ganey P.E., Cockrell G.L., Roth R.A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. Journal of Pharmacology and Experimental Therapeutics 2003, 307:9-16.
104. MacGregor T.R., Hall D.B. Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary metabolites. HIV Clinical Trials 2007, 8:391-399.
105. Maddrey W.C., Boitnott J.K. Isoniazid hepatitis. Annals of Internal Medicine 1973, 79:1-12.
106. Martin A.M., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proceedings of the National Academy of Sciences 2004, 101:4180-4185.
107. Martin A.M., Nolan D., James I., Cameron P., Keller J., Moore C., et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005, 19:97-99.
108. Masson M.J., Uetrecht J.P. Tolerance induced by low dose d-penicillamine in the Brown Norway rat model of drug-induced autoimmunity is immune-mediated. Chemical Research in Toxicology 2004, 17:82-94.
109. Masubuchi Y., Bourdi M., Reilly T.P., Graf M.L., George J.W., Pohl L.R. Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochemical and Biophysical Research Communications 2003, 304:207-212.
110. Masubuchi Y., Kano S., Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006, 222:233-239.
111. Masubuchi Y., Suda C., Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. Journal of Hepatology 2005, 42:110-116.
112. McGee J.H., Erikson D.J., Galbreath C., Willigan D.A., Sofia R.D. Acute, subchronic, and chronic toxicity studies with felbamate, 2-phenyl-1,3-propanediol dicarbamate. Toxicological Sciences 1998, 45:225-232.
113. Metushi I.G., Cai P., Zhu X., Nakagawa T., Uetrecht J.P. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clinical Pharmacology & Therapeutics 2011, 89:911-914.
114. Mirtcheva J., Pfeiffer C., De Bruijn J.A., Jacquesmart F., Gleichmann E. Immunological alterations inducible by mercury compounds. III. H-2A acts as an immune response and H-2E as an immune " suppression" locus for HgCl2-induced antinucleolar autoantibodies. Europen Journal of Immunology 1989, 19:2257-2261.
115. Mitchell J.R., Jollow D.J., Potter W.Z., Davis D.C., Gillette J.R., Brodie B.B. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. Journal of Pharmacology and Experimental Therapeutics 1973, 187:185-194.
116. Mitchell J.R., Zimmerman H.J., Ishak K.G., Thorgeirsson U.P., Timbrell J.A., Snodgrass W.R., et al. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Annals of Internal Medicine 1976, 84:181-192.
117. Moeschlin S., Wagner K. Agranulocytosis due to the occurrence of leukocyte-agglutinins. Acta Haematologica 1952, 8:29-41.
118. Morgan E.T. Regulation of cytochrome P450 by inflammatory mediators: why and how. Drug Metabolism and Disposition 2001, 29:207-212.
119. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
120. Myers T.G., Dietz E.C., Anderson N.L., Khairallah E.A., Cohen S.D., Nelson S.D. A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3'-hydroxyacetanilide. Chemical Research in Toxicology 1995, 8:403-413.
121. Naisbitt D.J., Ruscoe J.E., Williams D., O'Neill P.M., Pirmohamed M., Park B.K. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. Journal of Pharmacology and Experimental Therapeutics 1997, 280:884-893.
122. Neftel K.A., Woodtly W., Schmid M., Frick P.G., Fehr J. Amodiaquine induced agranulocytosis and liver damage. British Medical Journal 1986, 292:721-723.
123. Nelson S.D., Mitchell J.R., Timbrell J.A., Snodgrass W.R., Corcoran G.B. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science 1976, 193:901-903.
124. Noli C., Koeman J.P., Willemse T. A retrospective evaluation of adverse reactions to trimethoprim-sulphonamide combinations in dogs and cats. Veterinary Quarterly 1995, 17:123-128.
125. O'Brien P.J., Slaughter M.R., Polley S.R., Kramer K. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats. Laboratory Animals 2002, 36:313-321.
126. Obach R.S., Kalgutkar A.S., Soglia J.R., Zhao S.X. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chemical Research in Toxicology 2008, 21:1814-1822.
127. Ong M.M.K., Latchoumycandane C., Boelsterli U.A. Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicological Sciences 2007, 97:205-213.
128. Ong M.M.K., Wang A.S., Leow K.Y., Khoo Y.M., Boelsterli U.A. Nimesulide-induced hepatic mitochondrial injury in heterozygous Sod2+/- mice. Free Radical Biology & Medicine 2006, 40:420-429.
129. Padma P., Setty O.H. Protective effect of Phyllanthus Fraternus against carbon tetrachloride-induced mitochondrial dysfunction. Life Sciences 1999, 64:2411-2417.
130. Patel S.M., Johnson S., Belknap S.M., Chan J., Sha B.E., Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes 2004, 35:120-125.
131. Peterson M.E., Aucoin D.P., Davis C.A., Graves T.K. Altered disposition of propylthiouracil in cats with hyperthyroidism. Research in Veterinary Science 1988, 45:1-3.
132. Peterson M.E., Hurvitz A.I., Leib M.S., Cavanagh P.G., Dutton R.E. Propylthiouracil-associated hemolytic anemia, thrombocytopenia, and antinuclear antibodies in cats with hyperthyroidism. Journal of the American Veterinary Medical Association 1984, 184:806-808.
133. Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. Handbook of Experimental Pharmacology 2010, 196:477-491.
134. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clinical Therapeutics 1998, 20:1071-1092.
135. Pollmächer T., Haack M., Schuld A., Kraus T., Hinze-Selch D. Effects of antipsychotic drugs on cytokine networks. Journal of Psychiatric Research 2000, 34:369-382.
136. Popovic M., Caswell J.L., Mannargudi B., Shenton J.M., Uetrecht J.P. Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Chemical Research in Toxicology 2006, 19:1205-1214.
137. Popovic M., Nierkens S., Pieters R., Uetrecht J. Investigating the role of 2 phenylpropenal in felbamate-induced idiosyncratic drug reactions. Chemical Research in Toxicology 2004, 17.
138. Quddus J., Johnson K.J., Gavalchin J., Amento E.P., Chrisp C.E., Yung R., et al. Treating activated CD4+Tcells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. Journal of Clinical Investigations 1993, 92:38-53.
139. Ramachandran A., Lebofsky M., Weinman S.A., Jaeschke H. The impact of partial manganese superoxide dismutase (SOD2)-deficiency on mitochondrial oxidant stress, DNA fragmentation and liver injury during acetaminophen hepatotoxicity. Toxicology and Applied Pharmacology 2011, 251:226-233.
140. Reilly T.P., Brady J.N., Marchick M.R., Bourdi M., George J.W., Radonovich M.F., et al. A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chemical Research in Toxicology 2001, 14:1620-1628.
141. Remmen H.V., Salvador C., Yang H., Huang T.T., Epstein C.J., Richardson A. Characterization of the antioxidant status of the heterozygous manganese superoxide dismutase knockout mouse. Archives of Biochemistry and Biophysics 1999, 363:91-97.
142. Reynolds E.S., Moslen M.T. Halothane hepatotoxicity: enhancement by polychlorinated biphenyl pretreatment. Anesthesiology 1977, 47:19-27.
143. Rhodes J. Evidence for an intercellular covalent reaction essential in antigen-specific T cell activation. Journal of Immunology 1989, 143:1482-1489.
144. Richardson B., Scheinbart L., Strahler J., Gross L., Hanash S., Johnson M. Evidence for impared T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheumatism 1990, 33:1665-1673.
145. Richardson B.C., Strahler J.R., Pivirotto T.S., Quddus J., Bayliss G.E., Gross L.A., et al. Phenotypic and functional similarities between 5 azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheumatism 1992, 35:647-662.
146. Roller S.G., Dieckhaus C.M., Santos W.L., Sofia R.D., Macdonald T.L. Interaction between human serum albumin and the felbamate metabolites 4-hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal. Chemical Research in Toxicology 2002, 15:815-824.
147. Rubin R.L. Drug-induced lupus. Toxicology 2005, 209:135-147.
148. Rubin R.L., Burlingame R.W., Arnott J.E., Totoritis M.C., McNally E.M., Johnson A.D. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide induced lupus. Journal of Immunology 1995, 154:2483-2493.
149. Ruddy M.J., Shen F., Smith J.B., Sharma A., Gaffen S.L. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil recruitment. Journal of Leukocyte Biology 2004, 76:135-144.
150. Sakurai K., Zou J.-P., Tschetter J.R., Ward J.M., Shearer G.M. Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2002, 129:186-196.
151. Sarich T.C., Adams S.P., Petricca G., Wright J.M. Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor. Journal of Pharmacology and Experimental Therapeutics 1999, 289:695-702.
152. Sarich T.C., Youssefi M., Zhou T., Adams S.P., Wall R.A., Wright J.M. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits. Archives in Toxicology 1996, 70:835-840.
153. Sayeh E., Uetrecht J.P. Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: failure of the Th1/Th2 paradigm. Toxicology 2001, 163:195-211.
154. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
155. Schuller-Levis G., Mehta P.D., Rudelli R., Sturman J. Immunologic consequences of taurine deficiency in cats. Journal of Leukocyte Biology 1990, 47:321-331.
156. Seago A., Jarman M., Foster A.B., Baker M. Identification of hydroxylaminoglutethimide as induced urinary metabolites of aminoglutethimide in C57BL/6 mice. Biological Oxidation of Nitrogen in Organic Molecules 1985, 149-1563. Ellis Horwood Ltd, Chichester. J.W. Forrod, L.A. Damani (Eds.).
157. Sharma A., Uetrecht J. Covalent binding of nevirapine in vitro and in vivo. The Toxicologist 2011, 120:323.
158. Shenton J.M., Chen J., Uetrecht J.P. Animal models of idiosyncratic drug reactions. Chemico-Biological Interactions 2004, 150:53-70.
159. Shenton J.M., Popovic M., Chen J., Masson M.J., Uetrecht J.P. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chemical Research in Toxicology 2005, 18:1799-1813.
160. Shenton J.M., Teranishi M., Abu-Asab M.S., Yager J.A., Uetrecht J.P. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chemical Research in Toxicology 2003, 16:1078-1089.
161. Shevach E.M., McHugh R.S., Piccirillo C.A., Thornton A.M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunological Reviews 2001, 182:58-67.
162. Shimizu S., Atsumi R., Itokawa K., Iwasaki M., Aoki T., Ono C., et al. Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Archives in Toxicology 2009, 83:701-707.
163. Sipes I.G., Brown B.R. An animal model of hepatotoxicity associated with halothane anesthesia. Anesthesiology 1976, 45:622-628.
164. Siraki A.G., Bonini M.G., Jiang J., Ehrenshaft M., Mason R.P. Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chemical Research in Toxicology 2007, 20:1038-1045.
165. Smith M.T. Mechanisms of troglitazone hepatotoxicity. Chemical Research in Toxicology 2003, 16:679-687.
166. Sodhi C.P., Rana S.V., Mehta S.K., Vaiphei K., Attari S., Mehta S. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug and Chemical Toxicology 1997, 20:255-269.
167. Stein H.B., Patterson A.C., Offer R.C., Atkins C.J., Teufel A., Robinson H.S. Adverse effects of d-penicillamine in rheumatoid arthritis. Annals of Internal Medicine 1980, 92:24-29.
168. Tasduq S.A., Kaiser P., Sharma S.C., Johri R.K. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wistar rats: a toxicity profile study. Hepatology Research 2007, 37:845-853.
169. Thompson C.D., Gulden P.H., Macdonald T.L. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chemical Research in Toxicology 1997, 10:457-462.
170. Thompson C.D., Kinter M.T., Macdonald T.L. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chemical Research in Toxicology 1996, 9:1225-1229.
171. Tingle M.D., Jewell H., Maggs J.L., O'Neill P.M., Park B.K. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochemical Pharmacology 1995, 50:1113-1119.
172. Tournade H., Pelletier L., Pasquier R., Vial M.C., Mandet C., Druet P. d-Penicillamine-induced autoimmunity in Brown-Norway rats. Similarities with HgCl2-induced autoimmunity. Journal of Immunology 1990, 144:2985-2991.
173. Trepanier L.A. Delayed hypersensitivity reactions to sulphonamides: syndromes, pathogenesis and management. Veterinary Dermatology 1999, 10:241-248.
174. Trepanier L.A. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:129-138.
175. Trepanier L.A., Danhof R., Toll J., Watrous D. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. Journal of Veterinary Internal Medicine 2003, 17:647-652.
176. Trepanier L.A., Ray K., Winand N.J., Spielberg S.P., Cribb A.E. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to absence of NAT genes. Biochemical Pharmacology 1997, 54:73-80.
177. Uetrecht J. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. Drug Metabolism Reviews 1992, 24:299-366.
178. Uetrecht J. N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metabolism Reviews 2002, 34:651-665.
179. Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS Journal 2005, 7:E914-921.
180. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annual Review of Pharmacology and Toxicology 2007, 47:513-539.
181. Uetrecht J. Immunoallergic drug-induced liver injury in humans. Seminars in Liver Disease 2009, 29:383-392.
182. Uetrecht J.P., Ma H.M., MacKnight E., McClelland R. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chemical Research in Toxicology 1995, 8:226-233.
183. Usui T., Mise M., Hashizume T., Yabuki M., Komuro S. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metabolism and Disposition 2009, 37:2383-2392.
184. Vitezica Z.G., Milpied B., Lonjou C., Borot N., Ledger T.N., Lefebvre A., et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008, 22:540-541.
185. Waldhauser L., Uetrecht J. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils: implications for agranulocytosis. Drug Metabolism and Disposition 1991, 19:354-359.
186. Waldhauser L., Uetrecht J. Antibodies to myeloperoxidase in propylthiouracil-induced autoimmune disease in the cat. Toxicology 1996, 114:155-162.
187. Waring J.F., Liguori M.J., Luyendyk J.P., Maddox J.F., Ganey P.E., Stachlewitz R.F. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammatory chemokines and neutrophils. Journal of Pharmacology and Experimental Therapeutics 2005, 316:1080-1087.
188. Warrington R.J., McPhilips-Feener S., Rutherford W.J. The predictive value of the lymphocyte transformation test in isoniazid-associated hepatitis. Clinical Allergy 1982, 12:217-222.
189. Warrington R.J., Tse K.S., Gorski B.A., Schwenk R., Sehon A.H. Evaluation of isoniazid-associated hepatitis by immunological tests. Clinical & Experimental Immunology 1978, 32:97-104.
190. Williams D.P., Pirmohamed M., Naisbitt D.J., Uetrecht J.P., Park B.K. Induction of metabolism-dependent and -independent neutrophil apoptosis by clozapine. Molecular Pharmacology 2000, 58:207-216.
191. Wong K.H., Chan K.C., Lee S.S. Sex differences in nevirapine rash. Clinical Infectious Diseases 2001, 33:2096-2098.
192. You Q., Cheng L., Ju C. Generation of T cell responses targeting the reactive metabolite of halothane in mice. Toxicology Letters 2010, 194:79-85.
193. You Q., Cheng L., Reilly T.P., Wegmann D., Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology 2006, 44:1421-1431.
194. Yuan J., Guo S., Hall D., Cammett A.M., Jayadev S., Distel M., et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Aids 2011, 25:1271-1280.
195. Yung R., Chang S., Hemati N., Johnson K., Richardson B. Mechanisms of drug induced lupus IV: comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis & Rheumatism 1997, 40:1436-1443.
196. Yung R., Powers D., Johnson K., Amento E., Carr D., Laing T., et al. Mechanisms of drug induced lupus II: T cells overexpressing lymphocyte function-associated antigen 1 become autroreactive and cause lupuslike disease in syngeneic mice. Journal of Clinical Investgations 1996, 97:2866-2871.
197. Yung R.L., Quddus J., Chrisp C.E., Johnson K.J., Richardson B.C. Mechanisms of drug induced lupus I: cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. Journal of Immunology 1995, 154:3025-3035.
198. Zhu X., Li J., Liu F., Uetrecht J.P. Involvement of T helper 17 cells in d-penicillamine-induced autoimmune disease in Brown Norway rats. Toxicological Sciences 2011, 120:331-338.
199. Zimmerman H. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on The Liver 1999, Lippincott Williams and Wilkins, Philadelphia. second ed.